#United States #Salt Lake City #Co-Diagnostics #CoSara #Ebola Test

Co-Diagnostics Collaborates with CoSara for Ebola Testing

Co-Diagnostics, Inc. (NASDAQ: CODX), a pioneering molecular diagnostics firm, is making significant strides in the field of viral diagnostics through its joint venture with CoSara Diagnostics Pvt. Ltd. in India. The partnership recently announced the shipment of SARAGENE® Bundibugyo Virus Test kits to an independent laboratory for evaluation, marking a crucial step in addressing viral threats such as Ebola.

Testing for Ebola Virus: A New Approach

The coordinated effort follows a request from the India Centre for Cellular and Molecular Platforms (C-CAMP), a key initiative backed by India’s Department of Biotechnology. Co-Diagnostics also shared the successful completion of a proof-of-concept study for an extraction-free Ebola test, utilizing the Co-Dx PCR Pro® system with diluted plasma samples. This innovative approach signifies the first application of a blood-borne assay using the Co-Dx PCR Pro® point-of-care instrument, indicating promising advancements in diagnostic technology.

CEO Dwight Egan highlighted the urgency of these developments against the backdrop of recent Ebola outbreaks in Africa, emphasizing the critical need for effective diagnostic preparedness and public health response mechanisms. Egan praised the responsiveness of Co-Diagnostics to Indian public health requests, while also showcasing the enhanced capabilities of their Co-Dx PCR platform.

Expanding Diagnostic Horizons

The analytical studies involving the Bundibugyo tests aim to assess and refine the assay's detection limits, repeatability, and reproducibility. Initiated after C-CAMP's request for 200 test kits, these studies underscore India's commitment to enhancing its pandemic readiness through self-sufficient diagnostic capabilities. C-CAMP's InDx 2.0 National Diagnostics Catapult, launched in 2023, aims to empower India’s diagnostic ecosystem and ensure preparedness for current and future health crises.

The Bundibugyo test, crafted using Co-Diagnostics’ patented Co-Primers technology, targets one species linked to Ebola virus disease, which has been pivotal in recent outbreaks in both East and Central Africa. Furthermore, CoSara is in the process of developing a second-generation pan-Ebola assay intended for broad-spectrum detection of multiple Ebola species. This innovation aims to facilitate rapid laboratory confirmation and effective outbreak responses, especially in regions at risk.

Looking Ahead: The Future of Diagnostics

In addition to their commitment to Ebola diagnostics, Co-Diagnostics continues to expand the Co-Dx PCR platform's capabilities beyond traditional swab-based infectious disease testing. This advancement envisions an array of future applications and menu expansions in diagnostics, showcasing the firm’s dedication to innovation and improving health outcomes globally.

As these endeavors progress, the Co-Dx PCR platform, which includes comprehensive systems such as PCR Home® and mobile applications, remains subject to regulatory reviews in various jurisdictions, including the FDA in the U.S. While not available for sale yet, the platform's potential is vast.

Co-Diagnostics and CoSara represent a collaborative effort to enhance global health preparedness through advanced diagnostic solutions. This partnership illustrates the vital role of technology in addressing emerging health threats and strengthening public health infrastructures worldwide.

Conclusion

The partnership between Co-Diagnostics and CoSara marks a significant milestone in the fight against viral diseases like Ebola. Through innovative testing methods and a commitment to preparedness, they are setting a standard for future responses to health crises, emphasizing the importance of rapid and effective diagnostics in public health management.